SEI Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.43M Sell
138,346
-24,060
-15% -$1.16M 0.01% 1364
2026
Q1
$8.39M Buy
162,406
+7,795
+5% +$397K 0.01% 1233
2025
Q4
$7.68M Buy
154,611
+1,155
+0.8% +$56.2K 0.01% 1179
2025
Q3
$7.33M Sell
153,456
-116,450
-43% -$4.69M 0.01% 1139
2025
Q2
$8.51M Buy
269,906
+25,807
+11% +$827K 0.01% 1050
2025
Q1
$7.99M Sell
244,099
-52,816
-18% -$1.87M 0.01% 1063
2024
Q4
$10.7M Sell
296,915
-16,825
-5% -$592K 0.01% 956
2024
Q3
$9.78M Sell
313,740
-23,918
-7% -$746K 0.01% 1005
2024
Q2
$9.03M Buy
337,658
+7,078
+2% +$205K 0.01% 973
2024
Q1
$11.3M Buy
330,580
+64,752
+24% +$1.93M 0.02% 861
2023
Q4
$7.69M Sell
265,828
-1,446
-0.5% -$38.3K 0.01% 999
2023
Q3
$7.37M Sell
267,274
-1,451
-0.5% -$44.2K 0.01% 990
2023
Q2
$8.08M Sell
268,725
-36,362
-12% -$1.27M 0.01% 981
2023
Q1
$11.1M Buy
305,087
+37,490
+14% +$1.44M 0.02% 781
2022
Q4
$9.55M Buy
267,597
+23,076
+9% +$802K 0.02% 748
2022
Q3
$8.28M Buy
244,521
+18,127
+8% +$590K 0.02% 852
2022
Q2
$6.55M Buy
226,394
+3,245
+1% +$92.9K 0.01% 970
2022
Q1
$7.22M Buy
223,149
+5,196
+2% +$159K 0.01% 928
2021
Q4
$6.36M Sell
217,953
-7,233
-3% -$219K 0.01% 1009
2021
Q3
$6.01M Buy
225,186
+26,238
+13% +$704K 0.01% 998
2021
Q2
$6.13M Buy
198,948
+17,645
+10% +$541K 0.01% 974
2021
Q1
$4.75M Sell
181,303
-40,773
-18% -$1.14M 0.01% 1046
2020
Q4
$5.59M Sell
222,076
-18,786
-8% -$404K 0.01% 923
2020
Q3
$5.02M Buy
240,862
+22,831
+10% +$518K 0.01% 867
2020
Q2
$5.18M Buy
218,031
+59,489
+38% +$1.31M 0.02% 844
2020
Q1
$2.85M Sell
158,542
-155,435
-50% -$3.27M 0.01% 1000
2019
Q4
$7.45M Sell
313,977
-5,154
-2% -$125K 0.02% 711
2019
Q3
$8.75M Buy
319,131
+97,345
+44% +$2.88M 0.02% 655
2019
Q2
$7.38M Buy
221,786
+15,353
+7% +$526K 0.02% 731
2019
Q1
$7.26M Sell
206,433
-9,507
-4% -$354K 0.02% 706
2018
Q4
$10.3M Buy
215,940
+30,577
+16% +$1.31M 0.04% 534
2018
Q3
$9.34M Sell
185,363
-42,275
-19% -$2.09M 0.03% 558
2018
Q2
$13.6M Sell
227,638
-4,464
-2% -$231K 0.05% 434
2018
Q1
$10.6M Buy
232,102
+3,546
+2% +$148K 0.04% 487
2017
Q4
$9.11M Sell
228,556
-19,637
-8% -$776K 0.03% 647
2017
Q3
$9.93M Sell
248,193
-11,892
-5% -$515K 0.04% 604
2017
Q2
$11.2M Buy
260,085
+60,303
+30% +$2.15M 0.04% 504
2017
Q1
$6.25M Sell
199,782
-7,316
-4% -$196K 0.03% 698
2016
Q4
$5.23M Buy
207,098
+52,418
+34% +$1.17M 0.03% 742
2016
Q3
$3.82M Buy
154,680
+6,510
+4% +$147K 0.02% 816
2016
Q2
$3.02M Buy
148,170
+5,703
+4% +$101K 0.02% 842
2016
Q1
$2.17M Sell
142,467
-69,926
-33% -$912K 0.01% 948
2015
Q4
$2.85M Buy
212,393
+75,673
+55% +$1.17M 0.02% 859
2015
Q3
$1.92M Buy
136,720
+65,320
+91% +$1.21M 0.02% 820
2015
Q2
$1.21M Buy
+71,400
New +$1.02M 0.01% 921

Other funds holding SUPN

SEI Investments's SUPN Position: Q2 2026 in Review

SEI Investments reduced its Supernus Pharmaceuticals (SUPN) stake by 15% in Q2 2026, selling an estimated $1.16M and leaving 138,346 shares worth $6.43M. The position accounts for 0.01% of the portfolio, ranked #1364.

SEI Investments first reported a position in SUPN in Q2 2015 and has held it in 45 quarters since. The position peaked at $13.6M in Q2 2018. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • SEI Investments held 138,346 shares of Supernus Pharmaceuticals worth $6.43M as of Q2 2026.
  • SEI Investments sold 24,060 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.16M.
  • Supernus Pharmaceuticals made up 0.01% of SEI Investments's portfolio in Q2 2026, its #1364 holding.
  • SEI Investments first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
  • SEI Investments's Supernus Pharmaceuticals position peaked at $13.6M in Q2 2018.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.